New combo vaccine and immunotherapy tackles Hard-to-Treat breast cancer
NCT ID NCT03328026
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a personalized cancer vaccine (SV-BR-1-GM) combined with an immunotherapy drug (retifanlimab) in 36 people with advanced breast cancer that had stopped responding to standard treatments. The vaccine is made from the patient's own tumor cells and aims to train the immune system to attack the cancer. The study checked for safety and side effects, and also looked at whether tumors shrank. Results are not yet available, but the approach could offer a new option for patients with few choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SV-BR-1-GM (a personalized breast cancer cell vaccine), low-dose cyclophosphamide, interferon, and retifanlimab (an immunotherapy drug)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced breast cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 36 participants, so results may not apply to everyone. The treatment may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center of Kansas (CCK)
Wichita, Kansas, 67214, United States
-
Carle Cancer Institute
Urbana, Illinois, 61801, United States
-
Hematology-Oncology Associates of Fredericksburg, Inc
Fredericksburg, Virginia, 22408, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Manhattan Hematology Oncology Associates (MHOA)
Manhattan, New York, 10016, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Overlook Medical Center Oncology Research, Atlantic Health System
Summit, New Jersey, 07901, United States
-
St Vincent-Frontier Cancer Center
Billings, Montana, 59102, United States
-
St. Joseph Heritage Healthcare
Santa Rosa, California, 95403, United States
-
The Center for Cancer and Blood Disorders a division of American Oncology Partners MD
Bethesda, Maryland, 20817, United States
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
-
University of Miami/Sylvester at Plantation
Plantation, Florida, 33324, United States